TC-133

TC-133 is a preclinical-stage monoclonal antibody being developed by Foundery Biosciences for the treatment of cancer. As part of Foundery's pipeline of next-generation immunomodulators, TC-133 is designed to target novel pathways within the tumor microenvironment to enhance anti-tumor immune responses. The drug candidate emerged from Foundery's research platform, which focuses on the complex biology of T-cells and myeloid cells. While the specific molecular target of TC-133 has not been publicly disclosed, the program is positioned as a potential first-in-class therapy aimed at addressing unmet needs in immuno-oncology, particularly for patients who are non-responsive to existing checkpoint blockades.